
The Best Resveratrol Supplement for Healthy Anti-Aging Longevity Support: GenuinePurity Resveratrol
New York, May 03, 2025 (GLOBE NEWSWIRE) —
The best resveratrol supplement could help you age better by supporting cardiovascular health, metabolic efficiency, cognitive preservation, cellular resilience, and more.
Resveratrol is a potent antioxidant found in trace amounts in red grapes, blueberries, cranberries, and soybeans. It's more highly concentrated in some plants, such as Japanese knotweed (Polygonum cuspidatum) and certain pine tree species.
In recent years, resveratrol has gained notoriety as a reliable, longevity-boosting health supplement. A clinical review published in 2021 states, 'Accumulating studies revealed that resveratrol could extend lifespan.' With that in mind, we set out to identify the best resveratrol supplement options available in 2025.
Who Specifically is the Resveratrol Supplement for Healthy Aging Best For?
Adults Seeking Cellular Health and Longevity
Resveratrol, a potent antioxidant, is a reliable ally for those seeking to shield their cells and foster a longer, healthier life. Its ability to combat oxidative stress, a significant contributor to aging, ensures optimal cellular function and a longer lifespan, providing a sense of reassurance to the audience.
Individuals Combating Oxidative Stress and Signs of Aging
Oxidative stress accelerates aging, leading to wrinkles, fatigue, and other signs of aging. Resveratrol neutralizes harmful free radicals, helping maintain youthful energy and overall vitality.
Those Focused on Heart Health and Circulation
Heart health is a cornerstone of longevity. Resveratrol, with its ability to bolster healthy circulation, maintain balanced cholesterol levels, and contribute to optimal cardiovascular function, is a secure choice for those prioritizing heart wellness, instilling a sense of security in the audience.
People Interested in Cognitive Support and Brain Health
Age-related cognitive decline can impact memory, focus, and mental clarity. Resveratrol has been studied for its potential neuroprotective properties, helping to protect brain cells and support cognitive function over time.
Active Individuals and Fitness Enthusiasts
Regular physical activity can put stress on muscles and joints. Resveratrol's anti-inflammatory properties help support joint mobility and muscle recovery, making it a valuable supplement for active individuals.
Anyone Focused on Metabolism and Weight Management
Resveratrol may improve metabolic function, insulin sensitivity, and natural weight management. Supporting energy balance helps individuals maintain a healthy weight more effectively.
Women and Men Seeking Youthful, Radiant Skin
Collagen production naturally declines with age, leading to sagging skin and wrinkles. Resveratrol supports skin elasticity, helps reduce free radical damage, and promotes a firmer, more youthful complexion.
Resveratrol is a science-backed supplement that supports overall wellness, from heart and brain health to metabolism and skin vitality. It is an excellent choice for those committed to healthy aging and long-term well-being.
Our Top 5 Best Resveratrol Supplement Options
We've thoroughly examined the market, comparing ingredient sourcing, compound purity, formula bioavailability, manufacturing practices, price-to-value ratio, user reviews, and other relevant factors.
After considering numerous resveratrol supplements, we've narrowed our list to 5 expertly crafted dietary aids.
Our top 5 best resveratrol supplements are: GenuinePurity Resveratrol – Best Resveratrol Supplement
Toniiq Resveratrol – Best Supplement Optionality
Gaia Herbs Resveratrol – Best Capsule Design
Bronson Resveratrol – Best Resveratrol Complex
Purest Vantage Resveratrol – Best Supporting Ingredients
We've concluded that GenuinePurity Resveratrol is the best resveratrol supplement in 2025. Designed with 99% pure trans-resveratrol (backed by rigorous third-party testing) and a cutting-edge bio-enhancement system, GenuinePurity Resveratrol should provide dynamic anti-aging support.
As outstanding as GenuinePurity Resveratrol is, we have little doubt that each of our handpicked top 5 best resveratrol supplements could offer you tangible health benefits with no known adverse side effects. Below, we'll give you an inside look at what makes these products the best.
What Is A Resveratrol Supplement Good For?
Traditionally, resveratrol-rich sources, such as Japanese knotweed, have been revered for their prodigious health-enhancing properties.
For centuries, Japanese knotweed root has been used in Japan and China to boost blood flow, bolster skin radiance, elevate digestive properties, mitigate joint stiffness, and enhance overall wellness.
Thanks to modern science, we understand that Japanese knotweed's pro-health capacity is primarily due to its robust resveratrol concentration. Thus, many contemporary longevity experts recommend resveratrol supplementation as a viable anti-aging mechanism.
Regularly using a high-quality resveratrol supplement could help:
Promote Cardiovascular Health
Resveratrol activates pathways that stimulate nitric oxide production. Nitric oxide induces blood vessel elasticity, supporting elevated blood flow.
New data indicates that resveratrol could be beneficial for heart health. A clinical review published in 2024 states, 'Experimental studies suggest that resveratrol exerts cardioprotective effects.'
Preserve Cognitive Wellness
Resveratrol may safeguard neurons from age-induced degradation by supporting the production of Brain-Derived Neurotrophic Factor, a protein vital to long-term neuronal wellness.
A study of 125 postmenopausal women found that those taking a resveratrol supplement exhibited a '33% improvement in overall cognitive performance' compared to those taking a placebo.
Upgrade Metabolic Efficiency
Resveratrol switches on AMP-activated protein kinase. This enzyme stokes increased cellular glucose uptake and body fat burning while inhibiting excess body fat retention.
Resveratrol has been linked to increased insulin sensitivity, a key component of a robust metabolism. A 2022 report in Nutrients noted studies suggest 'resveratrol improves insulin sensitivity and fasting glucose levels' in people with metabolic issues.
Strengthen The Immune System
Resveratrol helps neutralize free radicals, mitigating oxidative stress that could otherwise damage immune cells. It may even improve the ability of our most critical immune cells to confront potential dangers.
An analysis authored by European researchers stated that resveratrol 'has been shown to act directly on central players of both innate and adaptive immunity, such as macrophages, lymphocytes, and dendritic cells.'
Augment Cellular Resilience
Resveratrol activates sirtuins, a class of enzymes that modulate cellular stress responses, DNA repair, and energy production.
Resveratrol also induces antioxidant defenses and activates autophagy, a cellular cleaning process that removes dysfunctional components. A study published in Neuroscience Letters remarked that resveratrol 'reduces oxidative stress and enhances cell survival.'
In short, modern science suggests that using a high-grade resveratrol supplement may improve your aging process by positively impacting numerous pathways.
It's important to note that all our picks for the best resveratrol supplements are designed for daily use. Consistent consumption nourishes your cells and promotes progressive enhancements in various physiological processes, helping to turn back the hands of time.
An Inside Look At Our Top 5 Best Resveratrol Supplement Options
You need to use a high-quality resveratrol supplement to get the best results. Our picks for the best resveratrol supplements are undoubtedly the best options in 2025. Here's why.
GenuinePurity Resveratrol – Best Resveratrol Supplement
GenuinePurity Resveratrol is our choice for the #1 best resveratrol supplement in 2025.
Made in the USA, GenuinePurity Resveratrol has highly pure (99% pure), naturally sourced trans-resveratrol molecules and advanced bio-enhancing technology designed to deliver top-notch results.
GenuinePurity Resveratrol – Premium Characteristics
GenuinePurity Resveratrol has earned a reputation for success and dependable longevity support.
Its premium characteristics include:
99% Pure Trans-Resveratrol (Sourced From Japanese Knotweed Root) – GenuinePurity Resveratrol contains 99% pure trans-resveratrol. This naturally occurring, bioactive form of resveratrol is believed to be ideal for longevity support.
GenuinePurity Resveratrol's trans-resveratrol is sourced from Japanese knotweed root, nature's most trans-resveratrol-rich source. It should supply the cleanest resveratrol molecules, delivering palpable benefits without any reported adverse side effects.
Third-Party Authenticated Formula – The GenuinePurity Resveratrol formula has been examined, tested, and authenticated by a third-party laboratory, proving it's the real deal.
Independent researchers found that GenuinePurity Resveratrol comprises highly pure trans-resveratrol, has a safe microbial profile, and is free of potentially problematic heavy metals. The reports can be viewed on the official GenuinePurity Resveratrol webpage.
Liposomal Encapsulation Raises Bioavailability – GenuinePurity Resveratrol utilizes a non-GMO liposomal encapsulation system to enhance resveratrol's bioavailability.
Tiny lipid-based vesicles shield resveratrol molecules from stomach acid, ferrying more intact resveratrol into the small intestine, where it's absorbed into the bloodstream. Then, liposomal structures merge with cell membranes via liposomal fusion, elevating cellular uptake.
GenuinePurity Resveratrol is expertly engineered to deliver outstanding anti-aging support. A third-party laboratory has tested and authenticated its elite-level resveratrol, and its non-GMO liposomal encapsulation system increases its bioavailability.
GenuinePurity Resveratrol – Reported Benefits
GenuinePurity Resveratrol is well-endowed with the ability to promote a wide range of wellness benefits.
It could help: Improve Daily Energy Levels
Mitigate Joint Discomfort
Boost Skin Radiance
Support Elevated Blood Flow
Extend Cognitive Wellness
Promote Excess Fat Reduction
Fortify Immune System Operations
Maximize Longevity & Healthspan
By taking just two capsules a day, you could begin to notice some of these results within a matter of weeks. With continual daily usage, those benefits should continue to improve over time.
It's recommended that each once-daily serving of GenuinePurity Resveratrol be taken with a meal. You should also store GenuinePurity Resveratrol between 15-30℃ (59-86℉) for optimal formula preservation.
GenuinePurity Resveratrol – User Reviews
User reviews indicate that men and women worldwide are achieving excellent outcomes with GenuinePurity Resveratrol.
Here's what some had to say:
Robert L. said –
'I've been taking GenuinePurity Resveratrol for almost a year. I've noticed an improvement in my daily energy and overall vitality.'
Deborah C. said –
'My husband and I use GenuinePurity Resveratrol daily. Since beginning our regimen, we've both shed some body fat and feel more mentally alert. We plan to use this supplement forever.'
Thomas D. said –
'I've tried several resveratrol supplements. GenuinePurity Resveratrol is by far the best. My stamina is up, my mind is clear, and my joint stiffness has subsided. I recommend anyone dealing with the downsides of aging try it.'
Most GenuinePurity Resveratrol user reviews we encountered made similar statements. Many individuals noted feeling more energetic and revitalized.
GenuinePurity Resveratrol – Pricing
A bottle of GenuinePurity Resveratrol (30-day supply) costs $59, or about $1.97 a day. When you order in bulk, you'll save more.
For example: Order 3 Bottles, Pay $53/Bottle ($1.77/Day)
Order 6 Bottles, Pay $43.17/Bottle ($1.44/Day)
Whether you purchase one or six bottles, your order is backed by the manufacturer's 97-day money-back satisfaction guarantee. This allows you to open and use GenuinePurity Resveratrol with virtually no financial risk.
If you're less than 100% satisfied with your experience, return all packaging to the manufacturer so that it's received and processed within 97 days of your delivery date. Then, you'll be refunded for the purchase price of 2 used or opened bottles and all unopened, fully sealed bottles.
Where To Purchase GenuinePurity Resveratrol
We recommend purchasing GenuinePurity Resveratrol from the official GenuinePurity website. That's where we found the lowest prices, the 97-day money-back satisfaction guarantee, free continental USA shipping, excellent customer care, secure checkout, and other great perks.
Toniiq Resveratrol – Best Supplement Optionality
Toniiq Resveratrol is our pick for the #2 best resveratrol supplement 2025.
Available in multiple dosing sizes and blends, Toniiq Resveratrol offers excellent optionality while maintaining top-tier ingredient purity and quality.
Toniiq Resveratrol – Premium Characteristics
Toniiq Resveratrol has long been considered by many to be among the most trusted resveratrol brands.
Its premium characteristics include:
98% Pure Trans-Resveratrol (Sourced From Japanese Knotweed Root) – Toniiq Resveratrol consists of 98% pure trans-resveratrol. Of course, trans-resveratrol is the most bioactive and bioavailable form of resveratrol, making it ideal for longevity supplementation.
Toniiq Resveratrol derives all of its resveratrol molecules from the root of Japanese knotweed. As the natural world's most potent source of trans-resveratrol, Japanese knotweed has been celebrated for its remarkable health benefits for generations in Asia.
Third-Party Certified Formula – Toniiq Resveratrol has been tested and certified by independent researchers who verified the manufacturer's formula design claims.
Third-party lab reports indicate that Toniiq Resveratrol does contain high-quality trans-resveratrol and is free of harmful microbes and heavy metals.
Available In Multiple Variations – Toniiq Resveratrol is available in multiple variations that offer different doses and blends, some of which include other pro-longevity compounds like quercetin and NMN.
This makes Toniiq Resveratrol an excellent option for adults from all walks of life. Whether you're interested in using a resveratrol or a hybrid supplement, they have something for you.
With high-grade resveratrol backed by third-party researchers and multiple variations that provide diverse options, Toniiq Resveratrol could be an intriguing, longevity-boosting dietary aid for many men and women.
Toniiq Resveratrol – Reported Benefits
Toniiq Resveratrol is well-suited to support numerous health enhancements.
It could help: Reduce Fatigue
Lessen Joint Stiffness
Support Heart Health
Maintain Cognitive Capacity
Elevate Metabolic Processes
Boost Immune System Responses
Mitigate Age-Related Decline
Necessitating only two daily capsules, Toniiq Resveratrol could promote these outcomes in time. As with all our picks for the best resveratrol supplements, Toniiq Resveratrol is designed to be used consistently over the long term.
Consistent intake supports resveratrol-driven benefits that grow progressively with each passing day. However, the results you achieve may subside if you stop using Toniiq Resveratrol or any of our top five best resveratrol supplement options.
Toniiq Resveratrol – User Reviews
Scores of user reviews reveal that many individuals are thrilled with the results they've experienced while using Toniiq Resveratrol.
Here's what some had to say:
Jonathan V. said –
'I'm happy with Toniiq Resveratrol. After using it for a few months, I noticed that my daily energy and ability to concentrate all day are improving.'
Ronald H. said –
'My friend said he has had a lot of success with Toniiq Resveratrol and recommended it. That was great advice. I'm feeling 5 years younger than before. Try this stuff.'
Mary W. said –
'A year ago, I was struggling with my weight and motivation. Since I began taking Toniiq Resveratrol regularly, I've lost several pounds and now exercise regularly.'
We found that these user reviews echoed the sentiments of many we read. Regular users seem to be noticing improvements in physical well-being and energy.
Toniiq Resveratrol – Pricing
A container of Toniiq Resveratrol (30-day supply) sells for $29.97, or about $1 a day. When you subscribe for recurring orders, you can save more.
For example, when you commit to ordering five or more products in an auto-delivery to a single address, you'll save 15%, reducing your per-container cost to $25.47. Free shipping may be available in some locations.
Where To Purchase Toniiq Resveratrol
We recommend ordering Toniiq Resveratrol from the official Toniiq Store on Amazon. There, we found the best prices, savings for subscribers, free shipping to some locations, and good customer service.
Discover why thousands call this the best resveratrol supplement for energy, clarity, and healthy aging—try it for yourself.
Gaia Herbs Resveratrol – Best Capsule Design
Gaia Herbs Resveratrol is our selection for the #3 best resveratrol supplement 2025.
A unique dietary aid made by a reputable manufacturer in the USA, Gaia Herbs Resveratrol delivers trans-resveratrol inside vegan-friendly, liquid phyto-capsules designed to support rapid absorption.
Gaia Herbs Resveratrol – Premium Characteristics
Gaia Herbs Resveratrol has undoubtedly made a respected name for itself in the longevity supplement space.
Its premium characteristics include:
High-Quality Trans-Resveratrol – Gaia Herbs Resveratrol contains high-quality trans-resveratrol, providing users with nature's most bioactive form of this potent antioxidant. As discussed, trans-resveratrol is typically the preferred form for longevity supplementation.
A review of resveratrol's impact on cellular wellness published in BMC Chemistry found that trans-resveratrol is more potent than other resveratrol, such as cis-resveratrol and dihydro-resveratrol.
Japanese Knotweed Root Extract – On top of high-quality trans-resveratrol, Gaia Herbs Resveratrol is outfitted with a Japanese knotweed root extract. This should provide even more trans-resveratrol molecules to boost antioxidant activity and enhance longevity support.
According to the manufacturer, Gaia Herbs Resveratrol's Japanese knotweed is ecologically harvested and grown using pesticide-free, regenerative agricultural practices.
Liquid Phyto-Capsules Support Absorption—Gaia Herbs Resveratrol deploys its resveratrol inside liquid phyto-capsules designed to support formula preservation, more rapid absorption, and enhanced bioavailability.
These gel capsules form an airtight seal that shields resveratrol from environmentally induced degradation. They also help improve resveratrol's solubility, promoting elevated bioavailability.
Gaia Herbs Resveratrol contains high-quality trans-resveratrol, a Japanese knotweed root extract, and liquid phytocapsules, which should help most users achieve significant longevity gains.
Gaia Herbs Resveratrol – Reported Benefits
Gaia Herbs Resveratrol offers the chance to achieve substantial wellness improvements.
It could help: Boost Endurance
Raise Daily Energy
Strengthen Cardiovascular Health
Preserve Neuronal Integrity
Support Metabolic Efficiency
Promote Skin Firmness
It is recommended that you consume 2 Gaia Herbs Resveratrol liquid phyto-capsules daily. Each serving can be taken with food or water. It may be best to take your once-daily serving at approximately the same time daily.
As with all our picks for the best resveratrol supplement options in 2025, if you have significant health concerns, you'll want to consult a trained medical professional before using Gaia Herbs Resveratrol.
Gaia Herbs Resveratrol – User Reviews
Feedback from many users suggests that Gaia Herbs Resveratrol is a reliable option for longevity support.
Here's what some had to say:
Danica R. said –
'Gaia Herbs Resveratrol has been part of my routine for a while. It helps me feel more lively in the morning. It's also been good for my skin. I believe all women over 60 should try it.'
Sarah J. said –
'My girlfriend suggested I try Gaia Herbs Resveratrol. She's a health guru, so I took her advice seriously. This supplement has been great for me. I feel like my youthfulness has been restored.'
Alex C. said –
'Gaia Herbs Resveratrol is a quality product. I've noticed significant improvements after taking it for just a few months. I have nothing but good things to say about my experience.'
We found comments such as these commonplace in Gaia Herbs Resveratrol user reviews. Innumerable men and women appear satisfied with our #3 best resveratrol supplement in 2025.
Gaia Herbs Resveratrol – Pricing
A bottle of Gaia Herbs Resveratrol (25-day supply) costs $25.64, or about $1.03 daily. Subscribing to recurring deliveries reduces daily costs.
You could save 10-15% off that price depending on how many bottles you order. This would reduce your daily expenditure to between $0.88 and $0.93. Free shipping options may be available for subscribers.
Where To Purchase Gaia Herbs Resveratrol
We recommend purchasing Gaia Herbs Resveratrol from Amazon's official Gaia Herbs Store. That's where we found the best deals, subscription-based savings, reasonable shipping, and secure checkout.
The best resveratrol of 2025 is here—and it's helping people feel younger, think sharper, and live stronger.
Bronson Resveratrol – Best Resveratrol Complex
Bronson Resveratrol is our nominee for the #4 best resveratrol supplement in 2025.
Made with trans-resveratrol and a blend of additional polyphenols, Bronson Resveratrol offers potent antioxidant support and is formulated to empower vigor in men and women of all ages.
Bronson Resveratrol – Premium Characteristics
Bronson Resveratrol has received acclaim from countless users and some experts.
Its premium characteristics include:
Trans-Resveratrol (Derived From Japanese Knotweed) – Bronson Resveratrol, like many of the best resveratrol supplements, contains trans-resveratrol derived from Japanese knotweed.
Trans-resveratrol is the premier form of resveratrol. It's highly bioactive and more bioavailable than other resveratrol compounds, like cis-resveratrol. Japanese knotweed contains a large concentration of trans-resveratrol, which has been used to promote health in East Asia.
Grape Seed Extract (20% Polyphenols)—Bronson Resveratrol utilizes a grape seed extract containing 20% polyphenols for added antioxidant support.
Grape seed is rich in proanthocyanidins, a specific type of polyphenol. Thanks to their potent antioxidant capacity, proanthocyanidins offer benefits that could complement resveratrol quite well.
Red Wine Extract (10% Polyphenols)—Besides its trans-resveratrol and grape seed extract, Bronson Resveratrol utilizes a red wine extract containing 10% polyphenols.
This compound, extracted from red grape skin, supplies a blend of dynamic polyphenols with formidable antioxidant capabilities. It should help boost resveratrol's pro-longevity benefits.
With trans-resveratrol derived from Japanese knotweed, grape seed extract, and red wine extract, Bronson Resveratrol may deliver first-class antioxidant support, helping to promote optimal aging.
Bronson Resveratrol – Reported Benefits
Bronson Resveratrol is well-made to deliver comprehensive antioxidant support and upgrade longevity.
It could help: Boost Vitality
Stimulate Metabolic Wellness
Maintain Cognitive Capacity
Facilitate Cardiovascular Health
Enhance Immune System Operations
Promote Cellular Lifespan
Manufacturer specifications suggest ingesting 1-2 Bronson Resveratrol capsules daily. It may be best to begin with one capsule and scale up to 2 when needed. To help digestion and absorption, take every serving with food.
Bronson Resveratrol can be stored at room temperature, preferably away from excess light, heat, and moisture. Like all our selections for the best resveratrol supplement options, Bronson Resveratrol is designed for adults and should be kept out of the reach of children.
Bronson Resveratrol – User Reviews
Many Bronson Resveratrol user reviews signal that people are over the moon with this supplement.
Here's what some had to say:
Patrick F. said –
'I read some good things about Bronson Resveratrol. So, I decided to give it a chance. I'm delighted I did. The spring is back in my step.'
Donald K. said –
'My wife and I have been taking Bronson Resveratrol for a few weeks. We both agree that we feel more energetic. So far, we love what this supplement has done for us.'
Janice V. said –
'I recommend Bronson Resveratrol. I've used it for a long time and am very happy with my experience. It's been beneficial for my skin, metabolism, and overall outlook on life.'
Our analysis of Bronson Resveratrol user reviews revealed that many men and women seem to be reaping excellent rewards with our pick for the #4 best resveratrol supplement in 2025.
Bronson Resveratrol – Pricing
A container of Bronson Resveratrol (60-day supply) retails for $24.99, or about $0.42 a day. These figures are based on taking two capsules per day.
If you take just one capsule daily, your daily costs would fall to just $0.21. However, we've determined that most users should ingest two capsules daily for optimal anti-aging support.
Where To Purchase Bronson Resveratrol
We recommend ordering Bronson Resveratrol from the official Bronson Store on Amazon. We found the best prices, subscription-based savings, free shipping availability, and excellent customer care.
Experience the top-rated resveratrol that's changing the way people age—naturally, gently, powerfully.
Purest Vantage Resveratrol – Best Supporting Ingredients
Purest Vantage Resveratrol is our choice for the #5 best resveratrol supplement in 2025.
Constructed with a mix of resveratrol and a laundry list of supporting ingredients, Purest Vantage Resveratrol is packed with antioxidants that offer pro-longevity support.
Purest Vantage Resveratrol – Premium Characteristics
Purest Vantage Resveratrol has been widely praised and has accumulated a loyal user base.
Its premium characteristics include:
Trans-Resveratrol (Standardized Japanese Knotweed Extract): Purest Vantage Resveratrol contains a Japanese knotweed extract standardized to provide 50% trans-resveratrol. As you know, this is the most bioactive and likely most beneficial form of resveratrol.
Trans-resveratrol is the dominant form of resveratrol and should be the foundation of a good resveratrol supplement. It delivers dynamic antioxidant support and health benefits.
Green Tea & Acai Fruit Extracts—In addition to trans-resveratrol, Purest Vantage Resveratrol contains many supporting ingredients, including green tea and acai fruit extracts.
Green tea extract is rich in catechins, potent antioxidants that help mitigate oxidative stress and enable cellular resilience. Acai fruit extract contains a high concentration of flavonoids, which assist in neutralizing free radicals and promoting cardiovascular health.
Additional Support Ingredients – Purest Vantage Resveratrol also contains quercetin, grape seed extract, and red wine extract, which offer significant longevity support.
Quercetin is a flavonoid found in many fruits and vegetables. Its senolytic properties help the body clear out aged cells. Meanwhile, grape seed and red wine extracts supply additional antioxidant actions to accompany resveratrol.
With a standardized Japanese knotweed extract and a diverse array of supporting ingredients, Purest Vantage Resveratrol boasts well-rounded longevity enhancement capabilities.
Purest Vantage Resveratrol – Reported Benefits
Purest Vantage Resveratrol uses a unique blend of antioxidants to deliver anti-aging support.
It could help: Raise Energy Levels
Preserve Cognitive Abilities
Support Immune System Wellness
Improve Metabolic Efficiency
Promote Blood Flow
Increase Cellular Resilience
According to the manufacturer, users should take 2 Purest Vantage Resveratrol capsules daily. It may be preferable to ingest every serving with a meal to help ensure optimal digestion and nutrient absorption.
Purest Vantage Resveratrol should be stored in a cool, dry place and protected from excessive light. As with all our picks for the best resveratrol supplement options, pregnant or nursing mothers should consult a physician before using it.
Purest Vantage Resveratrol – User Reviews
Purest Vantage Resveratrol user reviews paint a positive picture of our pick for the #5 best resveratrol supplement in 2025.
Here's what some had to say:
Georgia H. said –
'Purest Vantage Resveratrol is worth every penny. Once I started taking it, I noticed an uptick in my happiness and well-being.'
Antonio Q. said –
'My wife made me start using Purest Vantage Resveratrol. However, it's me who's obsessed with this supplement now. I've experienced a ton of benefits.'
Andrew J. said –
'I'm 57, and I've been using Purest Vantage Resveratrol for about a month. It has helped me start exercising again. I feel great.'
Most of the Purest Vantage Resveratrol user reviews were almost identical to these. Many people spoke extremely highly of this well-rounded dietary aid.
Purest Vantage Resveratrol – Pricing
A bottle of Purest Vantage Resveratrol (30-day supply) costs $19.95, or about $0.67 a day. Subscription-based discounts are available.
When you subscribe, you can save an additional 10-15%. You'd pay between $16.96 and $17.95 per bottle. Free shipping may also be available for some subscribers.
Where To Purchase Purest Vantage Resveratrol
We recommend purchasing Purest Vantage Resveratrol from Amazon's official Purest Vantage Store. We found the best deals, subscription-based discounts, free shipping, and secure checkout methods there.
Which Is the Best Resveratrol Supplement For You?
As anti-aging science progresses, new longevity-support supplements continue to emerge. Based on the findings of breakthrough studies, resveratrol seems to be the chief among them.
If you want to improve your aging process and live with vigor well into your 60s, 70s, 80s, and even 90s, using the best resveratrol supplement options in 2025 should help.
Our in-depth market analysis suggests that these supplements are the best. We recommend GenuinePurity Resveratrol, our clear-cut #1 best resveratrol supplement in 2025. Contact: Leading Edge Health GenuinePurity
Leading Edge Health GenuinePurity Address: 6130 Elton Ave, Las Vegas, NV 89107
6130 Elton Ave, Las Vegas, NV 89107 Email: [email protected]
[email protected] Phone: Toll Free (in North America) 1-866-968-6643
Toll Free (in North America) 1-866-968-6643 International: (international calling code) 1-778-770-2961 (6am – 6pm PST).
Affiliate Disclosure & Disclaimer
Affiliate Disclosure
This article may contain affiliate links, which means we may receive a commission if you purchase a product through one of these links. This comes at no additional cost to you and helps support the maintenance of this website. Our recommendations are based on research, product reviews, and general knowledge, but we encourage readers to do their due diligence before purchasing.
We strive to provide honest and unbiased information; however, including affiliate links may influence the products or brands mentioned in this content. Please assume that any links leading to products or services are affiliate links, and we may receive compensation for purchases made through them.
Medical Disclaimer
The information provided in this article is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. It is not a substitute for professional medical guidance from a qualified healthcare provider.
Before taking any dietary supplement, including resveratrol, consult with a licensed physician or healthcare professional, especially if you are pregnant, nursing, have a medical condition, or are taking prescription medications. Individual results may vary, and the effectiveness of supplements depends on multiple factors, including lifestyle, diet, and overall health.
The Food and Drug Administration (FDA) has not evaluated the statements regarding resveratrol supplements. These products are not intended to diagnose, treat, cure, or prevent any disease.
Liability Disclaimer
The publisher, authors, and all affiliated parties assume no responsibility for any adverse effects, health issues, or consequences arising from resveratrol supplements or reliance on the information provided in this article. While we strive for accuracy, we cannot guarantee that all information is up-to-date, complete, or error-free. Readers should research and consult with medical professionals before making health-related decisions.
By using this website and reading this content, you acknowledge and agree that any actions you take based on the information provided are at your own risk.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
an hour ago
- Business Upturn
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
By GlobeNewswire Published on June 12, 2025, 11:00 IST In the Phase IIIB APPULSE-PNH study, adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who switched to Fabhalta experienced clinically meaningful improvements in hemoglobin (Hb) levels of 2.01 g/dL on average 1,2 APPULSE-PNH evaluated Fabhalta in a population with higher baseline hemoglobin (Hb) levels than those enrolled in the pivotal Phase III program, expanding the clinical evidence base 1 ,2 No patients treated with Fabhalta required transfusions, experienced breakthrough hemolysis (BTH) or had any major adverse vascular events during the treatment period 1 Patients treated with Fabhalta reported an average improvement in fatigue from baseline of 4.88 points at Day 84 and 4.29 points at Day 168 of the study (as measured by FACIT-Fatigue score) 1 Basel, June 12, 2025 – Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) with Hb levels ≥10g/dL who switched from anti-C5 therapies (eculizumab or ravulizumab)1. After 24 weeks of treatment with Fabhalta, the Hb level improved on average by 2.01 g/dL (95% CI, 1.74, 2.29) with most patients achieving normal or near-normal levels 1. Data will be presented at the European Hematology Association (EHA) Congress 2025. 'Today, some patients living with PNH have unmet needs not addressed by eculizumab or ravulizumab,' said Austin Kulasekararaj, Consultant Hematologist, Kings College Hospital and Kings College London. 'The positive results from APPULSE-PNH reinforce that Fabhalta can provide clinically meaningful improvements in hemoglobin among patients with higher baseline hemoglobin levels than those enrolled in previous trials, while offering an oral monotherapy for patients.' No patients required transfusion during the study, and the vast majority (92.7%) achieved Hb ≥12g/dL, reaching normal or near-normal levels1. Patients treated with Fabhalta also reported clinically meaningful improvements in fatigue (as measured by FACIT-Fatigue score) through Day 168, reaching absolute levels similar to those reported in the general population1,3,4. Furthermore, patients treated with Fabhalta maintained intravascular hemolysis control and resolved extravascular hemolysis control, as demonstrated by lactate dehydrogenase levels (<1.5 upper limit of normal) and a reduction in absolute reticulocyte count1. 'Novartis is dedicated to advancing research and innovation that can transform care and significantly improve the lives of people living with PNH and those who support them,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer, Novartis. 'New data from APPULSE-PNH, combined with findings from the Phase III roll-over extension of the APPLY-PNH and APPOINT-PNH studies, reinforce the efficacy and safety profile of Fabhalta in delivering real benefits to patients. Fabhalta is the first and only oral monotherapy currently available for the treatment of adults with PNH, regardless of previous treatment experience.' Alongside APPULSE-PNH, longer-term data from patients initially included in the APPLY-PNH and APPOINT-PNH Phase III studies will be presented at EHA1. In APPULSE-PNH and the Phase III roll-over extension study of the APPLY-PNH and APPOINT-PNH studies, Fabhalta was well-tolerated with no new safety signals, consistent with previously reported data1,5. About paroxysmal nocturnal hemoglobinuria (PNH) PNH is a rare, chronic and serious complement-mediated blood disorder6. People with PNH have an acquired mutation in some of their hematopoietic stem cells (which are located in the bone marrow and can grow and develop into red blood cells [RBCs], white blood cells and platelets) that causes them to produce RBCs that are susceptible to premature destruction by the complement system6,7. This leads to intravascular hemolysis (destruction of RBCs within blood vessels) and extravascular hemolysis (destruction of RBCs mostly in the spleen and liver), which cause anemia (low levels of circulating RBCs), thrombosis (formation of blood clots), fatigue and other debilitating symptoms6,7. It is estimated that approximately 10-20 people per million worldwide live with PNH6. Although PNH can develop at any age, it is often diagnosed in people between 30-40 years old8,9. PNH has a significant unmet need not addressed by anti-C5 therapies (eculizumab or ravulizumab). Anti-C5 therapies (eculizumab or ravulizumab) are commonly administered every 2-8 weeks as intravenous infusions, and treatment visits (including journey, waiting, infusion and recovery time) can take approximately 4 to 5 hours10. Despite treatment with anti-C5 therapies, a large proportion of people with PNH remain anemic, and some dependent on blood transfusions7,11–16. About APPULSE-PNH APPULSE-PNH (NCT05630001) is a Phase IIIB, multinational, multicenter, single-arm, open-label study to evaluate the efficacy and safety of twice-daily oral Fabhalta® (iptacopan) monotherapy (200mg) in adults with PNH who were switched from anti-C5 therapies (eculizumab or ravulizumab)2. The trial enrolled 52 participants who received Fabhalta for 24 weeks2. Participants enrolled were required to be on a stable regimen with anti-C5 therapies (eculizumab or ravulizumab) for at least 6 months prior to screening with average hemoglobin (Hb) ≥10g/dL and no red blood cell transfusions in this period2,17. The primary endpoint is change from baseline Hb levels after 24 weeks of treatment with Fabhalta2,17. About APPLY-PNH APPLY-PNH (NCT04558918) is a Phase III, randomized, multinational, multicenter, active-comparator controlled, open-label trial to evaluate the efficacy and safety of twice-daily, oral Fabhalta® (iptacopan) monotherapy (200mg) for the treatment of PNH by demonstrating the superiority of Fabhalta compared to anti-C5 therapies (eculizumab or ravulizumab) in adult patients presenting with residual anemia (Hb <10 g/dl) despite a stable regimen of anti-C5 treatment in the last six months prior to randomization5,18. About APPOINT-PNH APPOINT-PNH (NCT04820530) is a Phase III, multinational, multicenter, open-label, single-arm study to evaluate the efficacy and safety of twice-daily, oral Fabhalta® (iptacopan) monotherapy (200mg) in adult PNH patients who are naïve to complement inhibitor therapy, including anti-C5 therapies (eculizumab or ravulizumab)19,20. About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway21,22. Discovered at Novartis, Fabhalta received US Food and Drug Administration (FDA) and European Commission (EC) approval in December 2023 and May 2024 respectively for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) and accelerated approval in the US in August 2024 for the reduction of proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression (generally UPCR ≥1.5 g/g 1.5 g/g)1,23,24. In 2025, Fabhalta received FDA and EC approval for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria, making it the first and only treatment approved for this condition25–31. Fabhalta is being studied in a broad range of rare kidney diseases, including atypical hemolytic uremic syndrome (aHUS), immune complex membranoproliferative glomerulonephritis (IC-MPGN) and lupus nephritis (LN). Studies are ongoing to evaluate the safety and efficacy profiles in these investigational indications and support potential regulatory submissions32-35. Disclaimer This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'plan,' 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'look forward,' 'believe,' 'committed,' 'investigational,' 'pipeline,' 'launch,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Novartis. Data on file. NCT05630001. Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan. (APPULSE). Available from: Accessed May, 2025. Montan I, Löwe B, Cella D, Mehnert A, Hinz A. General Population Norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale. Value Health. 2018;21(11):1313-1321. doi:10.1016/ Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528-538. doi:10.1002/cncr.10245 Peffault de Latour R, Röth A, Kulasekararaj AG, et al. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2024;390(11):994-1008. doi:10.1056/NEJMoa2308695 Cançado RD, Araújo ADS, Sandes AF, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematol Transfus Cell Ther. 2021;43(3):341-348. Dingli D, Matos JE, Lehrhaupt K, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022;101(2):251-263. Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. Röth A, Maciejewski J, Nishimura JI, Jain D, Weitz JI. Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. Eur J Haematol. 2018;101(1):3-11. Levy AR, Dysart L, Patel Y, et al. Comparison of Lost Productivity Due to Eculizumab and Ravulizumab Treatments for Paroxysmal Nocturnal Hemoglobinuria in France, Germany, Italy, Russia, Spain, the United Kingdom, and the United States. Blood. 2019;134(Supplement_1):4803. McKinley CE, Richards SJ, Munir T, et al. Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome. Blood. 2017;130(Supplement 1):3471. Risitano AM, Marotta S, Ricci P, et al. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. Front Immunol. 2019;10:1157. Shammo J, Kim J, Georget M, et al. P796: Hospitalization in patients with paroxysmal nocturnal hemoglobinuria: a retrospective analysis of observational study data from the United States. Hemasphere. 2023;7(Suppl):e22585a2. Debureaux PE, Kulasekararaj AG, Cacace F, et al. Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study. Bone Marrow Transplant. 2021;56(10):2600-2602. Schrezenmeier H, Kulasekararaj A, Mitchell L, et al. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. Ther Adv Hematol. 2020;11:2040620720966137. Young NS, Meyers G, Schrezenmeier H, Hillmen P, Hill A. The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients. Semin Hematol. 2009;46(1 Suppl 1):S1-S16. Risitano AM, Araten DJ, Kuter D, et al. Pb2063: APPULSE-PNH: A phase IIIB trial to evaluate the efficacy and safety of switching to iptacopan in patients with paroxysmal nocturnal hemoglobinuria (PNH) on anti-c5 therapy with hemoglobin >10g/dl. Hemasphere. 2023;7(Suppl):e08587b7. NCT04558918. Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment (APPLY-PNH). Available from: Accessed May, 2025. Risitano AM, Han B, Ueda Y, et al. Oral Complement Factor B Inhibitor Iptacopan Monotherapy Improves Hemoglobin to Normal/Near-Normal Levels in Paroxysmal Nocturnal Hemoglobinuria Patients Naïve to Complement Inhibitors: Phase III APPOINT-PNH Trial. Presented at: 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT); April 23-36, 2023; Paris, France. NCT04820530. Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy (APPOINT-PNH). Available from: Accessed May, 2025. Kavanagh D, Bomback A, Vivarelli M, et al. Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy: Results from the Phase 3 APPEAR-C3G Trial. Presented at European Renal Association (ERA) Congress; May 25, 2024; Stockholm, Sweden. Smith RJ, Kavanagh D, Vivarelli M, et al. Efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-Month results from the Phase 3 APPEAR-C3G study. Presented at American Society of Nephrology (ASN) Kidney Week 2024; October 23-27, 2024; San Diego, CA. Novartis. Press release. Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH. Available from: Accessed May, 2025. Novartis. Press release. Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN). Available from: Accessed May, 2025. Novartis. Press release. Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G). Available from: Accessed May, 2025. Novartis. Press release. Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G). Available from: Accessed May, 2025. Fabhalta®. US FDA Prescribing information. East Hanover, NJ:Novartis Pharmaceuticals Corp; 2024. Available from: Accessed May, 2025. Fabhalta®. EMA Summary of Product Characteristics. Novartis Europharm Limited; 2024. Available from: Accessed May, 2025. Martín B, Smith RJH. C3 Glomerulopathy. In: Adam MP, Feldman J, Mirzaa GM, et al, eds. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2025. Updated April 5, 2018. Available from: Accessed May, 2025. Schena FP, Esposito P, Rossini M. A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease. Int J Mol Sci. 2020;21(2):525. Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Update on C3 Glomerulopathy: A Complement-Mediated Disease. Nephron. 2020;144(6):272-280. NCT04578834. Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN). Available from: Accessed May, 2025. NCT04889430. Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS). Available from: Accessed May, 2025. NCT05755386. Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN (APPARENT). Available from: Accessed May, 2025. NCT05268289. Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V. Available from: Accessed May, 2025. # # # Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.


Business Upturn
an hour ago
- Business Upturn
Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison
Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax 1 Phase 2 CAPTIVATE long-term follow-up data further supports sustained efficacy and safety profile of fixed-duration ibrutinib plus venetoclax treatment in patients receiving frontline treatment for chronic lymphocytic leukaemia 2 Beerse, Belgium, June 12, 2025 (GLOBE NEWSWIRE) — Janssen-Cilag International NV, a Johnson & Johnson company, today announced new data from a matching-adjusted indirect comparison (MAIC) analysis assessing the efficacy of IMBRUVICA® (ibrutinib) in combination with venetoclax (I+V) vs acalabrutinib in combination with venetoclax (A+V) as fixed-duration (FD) treatments for adults with previously untreated chronic lymphocytic leukaemia (CLL).1 The data were featured in a poster presentation at the 30th European Hematology Association (EHA) Congress (Poster presentation #PF587) and reported that the I+V regimen yielded significantly better efficacy when compared to the A+V regimen.1 Patients treated with I+V were more likely to achieve disease clearance, as measured by undetectable minimal residual disease (uMRD) three months after the end of treatment (EOT+3), from both peripheral blood (PB) and bone marrow (BM).1 In addition to this, progression-free survival (PFS) significantly favoured I+V compared to A+V.1 'In the absence of head-to-head trials, clinicians need reliable tools to effectively compare treatment options and make the best possible choices for their patients,' said Talha Munir, M.D., Consultant in Clinical Haematology at St James's Hospital, Leeds, United Kingdom.* 'The matching-adjusted indirect comparison data presented at EHA suggests that ibrutinib plus venetoclax may offer meaningful clinical advantages over acalabrutinib plus venetoclax with patients more likely to achieve higher rates of undetectable minimal residual disease, three months after treatment. This may translate into more time in remission and longer progression-free survival – outcomes that matter deeply to both patients and the healthcare professionals who treat them.' Patients who met the AMPLIFY inclusion criteria from both the Phase 3 GLOW (NCT03462719) and Phase 2 CAPTIVATE (NCT02910583) studies were included in this analysis, and, after matching and balancing the treatment cohorts, comparative analyses between the trials suggested that I+V significantly reduced the risk of progression or death by 47 percent when compared to patients treated with A+V (hazard ratio [HR]: 0.53; 95 percent confidence interval [CI]: 0.33-0.85; p =0.0085).1,3,4,5 The results also suggested that patients treated with I+V were almost twice (95 percent CI: 1.47-2.41; p <0.0001) and 2.4 times (95 percent CI: 1.78-3.12; p <0.0001) more likely to achieve uMRD than A+V at EOT+3, in PB and BM, respectively.1 The GLOW and CAPTIVATE FD cohorts were based on individual patient-level data with a median follow-up of approximately 4.5 years, while the A+V cohort used aggregate level data from the AMPLIFY study with a median follow-up of approximately 3.4 years.1 Results from final analysis of CAPTIVATE Long-term follow-up results from the Phase 2 CAPTIVATE study data were presented as a poster at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (Poster presentation #219) and will also be presented as an encore oral presentation at EHA 2025 (Oral presentation #S156).6 The data reinforced the durable clinical benefit of frontline I+V.2 Phase 2 CAPTIVATE results demonstrated patients in the I+V FD cohort displayed a clinically meaningful PFS and overall survival (OS) vs the MRD-guided cohort.2 After a median follow-up of 68.9 months, the 5.5-year PFS and OS rates for all treated patients were 66 percent (95 percent CI: 58-72) and 97 percent (95 percent CI: 93-99), respectively.2 Additionally, the 5.5 year PFS rate in patients who achieved uMRD in the PB at the EOT was 71 percent (95 percent CI: 60-80).2 Furthermore, 1-year PFS and OS rates from the start of retreatment (with single-agent ibrutinib or FD I+V) were both 100 percent, whilst 2-year PFS and OS rates from the start of retreatment were 91 percent and 96 percent, respectively.2 No new safety signals were observed during the CAPTIVATE study since the previous follow-up, with COVID-19, diarrhoea and hypertension being the most frequently reported adverse events (AEs).2 In the total pooled CAPTIVATE population, 32 percent (n=64/202) of patients had progressive disease following 5.5 years of follow-up.2 Of the 53 patients with available samples, none had acquired resistance-associated mutations in BTK or PLCG2 .2 'The final analysis of CAPTIVATE highlights how ibrutinib continues to raise the bar in the treatment of chronic lymphocytic leukaemia, with durable minimal residual disease response, extended treatment-free intervals, and a tolerable safety profile,' said Ester in't Groen, EMEA Therapeutic Area Head Haematology, Johnson & Johnson Innovative Medicine. 'With the longest follow-up of any oral fixed-dose regimen, ibrutinib is setting a new standard for what patients and clinicians can expect from targeted therapies. We remain committed to advancing science in complex blood cancers and improving outcomes across the cancer care landscape.' 'The updates presented at EHA add to the growing body of evidence in support of ibrutinib, the most extensively studied Bruton's tyrosine kinase inhibitor, as the standard of care in the frontline treatment of chronic lymphocytic leukaemia,' said Jessica Vermeulen, Vice President, Lymphoma & Leukemia Disease Area Stronghold Leader, Johnson & Johnson Innovative Medicine. 'Offering patients not only more time, but also the option for treatment-free remissions continues to be our goal and we are proud of the incredible contribution ibrutinib has made since its first European approval in 2014.' About the MAIC analysis The objective of this analysis was to compare the progression-free survival (PFS) and undetectable minimal residual disease (uMRD) data from the fixed-duration (FD) ibrutinib + venetoclax (I+V) cohorts from the Phase 3 GLOW (NCT03462719) and Phase 2 CAPTIVATE (NCT02910583) studies against the Phase 3 AMPLIFY (NCT03836261) data.1 In absence of prospective head-to-head trials investigating different Bruton's tyrosine kinase inhibitors (BTKis) plus B-cell lymphoma 2 (Bcl-2) strategies, this study utilised matching-adjusted indirect comparison (MAIC) to obtain useful insights on comparative efficacy.1 Individual patient data from the FD I+V cohorts of the GLOW and CAPTIVATE studies were pooled and compared to aggregate published Intent-to-Treat (ITT) data of the acalabrutinib plus venetoclax (A+V) arm of the AMPLIFY study.1,3,4,5 A MAIC was performed following method published by Signorovitch et al. and guidelines from the National Institute for Health and Care Excellence (NICE).1,7 Patients who did not meet the inclusion criteria of AMPLIFY were excluded from the I+V pooled cohort to establish the I+V patient population for analysis.1 The remaining I+V patients were then reweighted so that the average baseline characteristics of the pooled I+V cohort matched those of the A+V patients in AMPLIFY.1 The reweighted outcomes from I+V were then compared to the reported outcomes for A+V using indirect treatment comparison.1 Relative effects were quantified using relative risk (RR) and hazard ratios (HR) with 95 percent confidence intervals.1 There are potential sources of bias that cannot be accounted for in MAIC, that should be considered when interpreting such data. Specifically, in this comparison, the measurement of progression was stricter in GLOW and CAPTIVATE, requiring computer or magnetic imaging regardless of suspected progression and the median follow-up was longer in I+V population.1 Both may have biased the PFS results in favour of A+V.1 Additionally, AMPLIFY reported multicolour flow cytometry use but with no details on the number of colours and comparability is assumed with the 8-colour assay used in I+V studies.1 As in any non-randomised comparison there may be additional unreported clinically important prognostic patient baseline characteristics which cannot be accounted for.1 For example, Cumulative Illness Rating Scale score data was not collected in CAPTIVATE and therefore could not be used in matching.1 About CAPTIVATE The Phase 2 CAPTIVATE study ( NCT02910583 ) evaluated previously untreated adult patients with chronic lymphocytic leukaemia (CLL), who were 70 years or younger, including patients with high-risk disease, in two cohorts with combined median age of 60 years: a minimal residual disease (MRD)-guided cohort (n=43) and an FD cohort (n=159; median age).2,4,8 Patients in the FD cohort received three cycles of ibrutinib lead-in followed by 12 cycles of I+V (oral ibrutinib [420 mg/d]; oral venetoclax [five-week ramp-up to 400 mg/d]) and the primary endpoint was complete response rate.4 In the MRD cohort, after completion of three cycles ibrutinib lead-in followed by 12 cycles I+V, patients with confirmed uMRD were randomly assigned to double-blind treatment with placebo, or continuous ibrutinib.4 The primary endpoint was one-year disease-free survival.4 About the GLOW study The GLOW study ( NCT03462719 ) is a randomised, open-label, Phase 3 trial that evaluated the efficacy and safety of frontline, FD I+V versus chlorambucil plus obinutuzumab in adult patients with CLL who are (a) ≥65 years old, or (b) 18-64 years old with a Cumulative Illness Rating Scale score of greater than six or creatinine clearance less than 70 mL/min, who had active disease requiring treatment per the International Workshop on CLL criteria.3 About ibrutinib Ibrutinib is a once-daily oral medication that is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company.9 Ibrutinib blocks the Bruton's tyrosine kinase (BTK) protein, which is needed by normal and abnormal B-cells, including specific cancer cells, to multiply and spread.10 By blocking BTK, ibrutinib may help move abnormal B-cells out of their nourishing environments and inhibits their proliferation.11 Ibrutinib is approved in more than 100 countries and has been used to treat more than 325,000 patients worldwide.12 There are more than 50 company-sponsored clinical trials, including 18 Phase 3 studies, over 11 years evaluating the efficacy and safety of ibrutinib.10,13 In October 2021, ibrutinib was added to the World Health Organization's Model Lists of Essential Medicines (EML), which refers to medicines that address global health priorities and which should be available and affordable for all.14 Ibrutinib was first approved by the European Commission (EC) in 2014, and approved indications to date include:10 As a single agent or in combination with rituximab or obinutuzumab or venetoclax for the treatment of adult patients with previously untreated CLL As a single agent or in combination with bendamustine and rituximab (BR) for the treatment of adult patients with CLL who have received at least one prior therapy As a single agent for the treatment of adult patients with relapsed or refractory (RR) mantle cell lymphoma (MCL) As a single agent for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. In combination with rituximab for the treatment of adult patients with WM For a full list of adverse events and information on dosage and administration, contraindications and other precautions when using ibrutinib please refer to the Summary of Product Characteristics . About Chronic Lymphocytic Leukaemia CLL is typically a slow-growing blood cancer of the white blood cells.15 The overall incidence of CLL in Europe is approximately 4.92 cases per 100,000 persons per year and it is about 1.5 times more common in men than in women (based on individuals diagnosed 2000-2002).16 CLL is predominantly a disease of the elderly, with a median age of 72 years at diagnosis.17 While patient outcomes have dramatically improved in the last few decades, the disease is still characterised by consecutive episodes of disease progression and the need for therapy.18 Patients are often prescribed multiple lines of therapy as they relapse or become resistant to treatments.19 About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at . Follow us at . Janssen-Cilag International NV, Janssen Pharmaceutica NV, Janssen-Cilag Limited, Janssen Biotech, Inc., and Janssen Research & Development, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of daratumumab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. *Talha Munir, M.D., Consultant in Clinical Haematology at St James's Hospital, Leeds, United Kingdom, has provided consulting, advisory, and speaking services to Janssen-Cilag International NV; he has not been paid for any media work. 1 Munir T, et al., Cross-Study Comparison of Ibrutinib in Combination with Venetoclax (I+V) vs Acalabrutinib in Combination with Venetoclax (A+V) in Subjects with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Poster presentation at 2025 European Hematology Association (EHA) Congress; June 12–15, 2025. [Poster PF587]. 2 Ghia P, et al. Final Analysis of Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study. Oral presentation at 2025 European Hematology Association (EHA) Congress; June 12–15, 2025. [Oral S156]. 3 A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW). Available at: Last accessed: June 2025. 4 Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) (CAPTIVATE). Available at: Last accessed: June 2025. 5 Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY). Available at: Last accessed: June 2025. 6 Ghia P, et al. Final Analysis of Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Phase 2 CAPTIVATE Study. Poster presentation at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting; May 30–June 3, 2025. [Poster #219]. 7 Signorovitch JE, et al. Matching-adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research. Value Health, 2012; 15: 940-947. 8 Jacobs R, et al., Outcomes in High-risk Subgroups After Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Up To 5.5 years of Follow-up in the Phase 2 CAPTIVATE Study. Poster presentation at 2024 European Hematology Association (EHA) Hybrid Congress; June 13–16, 2024. [Poster P675]. 9 European Medicines Agency. IMBRUVICA Summary of Product Characteristics. April 2025. Available at: Last accessed: June 2025. 10 Turetsky A, et al. Single cell Imaging of Bruton's tyrosine kinase using an Irreversible Inhibitor. Sci Rep. 2014; 4: 4782. 11 de Rooij MF, et al. The Clinically Active BTK Inhibitor PCI-32765 targets B-cell Receptor- and Chemokine-controlled Adhesion and Migration in Chronic Lymphocytic Leukemia. Blood. 2012; 119(11): 2590-2594. 12 J&J Data on File (RF-465355). Patients Treated on Imbruvica Worldwide. May 2025. 13 Pollyea DA, et al. A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. Blood. 2009; 114(22): 3713. 14 World Health Organization. WHO Prioritizes Access to Diabetes and Cancer Treatments in New Essential Medicines Lists. Available at: Last accessed: June 2025. 15 American Cancer Society. What is Chronic Lymphocytic Leukemia? Available at: Last accessed: June 2025. 16 Sant M, et al. Incidence of Hematologic Malignancies in Europe by Morphologic Subtype: Results of the HAEMACARE project. Blood. 2010; 116:3724–34. 17 Eichhorst B, et al. Chronic Lymphocytic Leukaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up Ann Oncol. 2021; 32(1): 23-33. 18 Moreno C. Standard Treatment Approaches for Relapsed/refractory Chronic Lymphocytic Leukemia after Frontline Chemoimmunotherapy. Hematology Am Soc Hematol Educ Program. 2020; 2020: 33-40. 19 Bewarder M, et al. Current Treatment Options in CLL. Cancers (Basel). 2021;13(10): 2468. CP-523458 June 2025 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
3 hours ago
- Yahoo
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE) At Week 48, more individuals receiving DZP experienced no or low disease activity compared to standard of care with differences observed as early as Week 12 BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology's annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO. 'Despite being a common manifestation of systemic lupus erythematosus, fatigue is a difficult-to-treat symptom that can severely impact a person's quality of life, and remains a challenge to address,' said Ioannis Parodis, MD, PhD, Associate Professor of Rheumatology, Karolinska University Hospital, Sweden. 'The results we observed in this Phase 3 study indicate that participants treated with dapirolizumab pegol have the potential to achieve consistent improvements in fatigue beyond the current standard of care.' In an analysis of the impact of DZP on patient-reported fatigue in people with SLE participating in the PHOENYCS GO study, individuals receiving DZP in addition to standard of care (SOC) treatment demonstrated improvements across two fatigue measurements: Improvements in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scores were greater in the DZP group (change from baseline, 8.9), compared with SOC alone (5.2; nominal* p=0.0024) at Week 48. Using FATIGUE-PRO, a measure recently developed to capture the patient experience of fatigue in SLE, greater improvements from baseline (nominal* p<0.05) were observed in people receiving DZP compared with SOC alone in the Physical Fatigue (change from baseline difference between groups,7.6), Mental and Cognitive (5.6), and Susceptibility to Fatigue (7.8) scales at Week 48. 'Being able to address both fatigue and remission are areas of critical unmet need in lupus care, an important treatment goal is to improve the quality of life for patients as well as to reduce the long-term risk of organ damage through disease remission,' said Eric F. Morand, MBBS, Head of the Monash Health Rheumatology Unit, Monash University, Australia. 'In the PHOENYCS GO study, dapirolizumab pegol has shown meaningful impact in helping patients achieve remission and low disease activity, offering the exciting possibility for improved disease control while reducing exposure to glucocorticoids. Dapirolizumab pegol has the potential to become a significant new medication for people living with SLE, as shown by the breadth of effect seen in the study and I look forward to seeing results from the second Phase 3 study.' In an additional analysis, improvements were seen on measures of low disease activity, as measured by Low Lupus Disease Activity State (LLDAS) and disease remission, as measured by Definition of Remission in SLE (DORIS). Both measures include assessments of disease activity, in addition to a required low dose glucocorticoid intake (<7.5 mg prednisone / day in LLDAS; <5 mg prednisone / day in DORIS). At Week 48, the percentage of participants achieving low disease activity in the DZP group was twice that of the SOC only group (40.9% and 19.6%, respectively; nominal* p<0.0001). As early as Week 12, greater proportions of participants receiving DZP plus SOC achieved LLDAS versus SOC alone (nominal* p<0.05). 23.6% of participants receiving DZP plus SOC achieved low disease activity in ≥50% of visits through 48 weeks compared with 15.9% receiving SOC alone (nominal* p=0.1042). A higher proportion of those receiving DZP (19.2%) versus SOC alone (8.4%) also achieved DORIS at Week 48 (nominal* p=0.0056). * Having met the primary endpoint, improvement of moderate-to-severe disease activity as assessed by achievement of BICLA after 48 weeks and the key secondary endpoint having a p-value = 0.1776, all subsequent secondary and tertiary endpoints are descriptive and nominal p-values are included. The safety profile of DZP was generally favorable. The safety results were consistent with previous DZP studies and with that in study participants with SLE receiving an immunomodulator. A higher proportion of individuals receiving DZP plus SOC had treatment-emergent adverse events (TEAEs) compared to SOC alone (82.6% vs. 75.0%). The proportion of participants with serious TEAEs was 9.9% in participants receiving DZP plus SOC was lower as compared to 14.8% in those receiving SOC alone. Discontinuation of treatment or study participation due to TEAEs occurred in 4.7% (10) of participants receiving DZP plus SOC and 3.7% (4) of participants receiving SOC alone. Participants from the PHOENYCS GO study (NCT04294667) will continue to be followed in a long-term open-label study. A second Phase 3 trial of dapirolizumab pegol, PHOENYCS FLY (NCT06617325) is ongoing. About Systemic Lupus Erythematosus (SLE)SLE is a chronic, multifactorial autoimmune disease that is caused by the activation of autoreactive T, B and antigen-presenting cells, resulting in manifestations across multiple organ systems with periods of illness or flares alternating with periods of inactivity.1 SLE can present itself in several ways including rash, arthritis, anemia, thrombocytopenia, serositis, nephritis, seizures or psychosis.2 SLE is associated with a greater risk of death from causes such as infection and cardiovascular disease. An estimated 90% of people living with lupus are women; most begin to see symptoms between the ages of 15-55.3,4,5 Individuals from populations of African, Hispanic, Asian and Native American descent are at a greater risk of earlier onset and more aggressive disease.6,7 Pregnancy in women with SLE is high risk, with higher maternal and fetal mortality and morbidity than the general population.8,9 About Dapirolizumab PegolDapirolizumab pegol is a novel investigational humanized Fc-free polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment. Dapirolizumab pegol inhibits CD40L signaling which has been shown to reduce B cell activation and autoantibody production, mitigate type 1 interferon (IFN) secretion, and attenuate T cell and antigen-presenting cell (APC) activation.10 Dapirolizumab pegol is presently in Phase 3 clinical development for the treatment of systemic lupus erythematosus (SLE) under a collaboration between UCB and Biogen.11 About UCBUCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. The company routinely posts information that may be important to investors on its website at Follow us on social media - Facebook, LinkedIn, X, YouTube. Forward looking statements UCBThis document contains forward-looking statements, including, without limitation, statements containing the words 'potential', 'believes', 'anticipates', 'expects', 'intends', 'plans', 'seeks', 'estimates', 'may', 'will', 'continue' and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document. Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring, retention and compliance of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems. Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB. UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. Biogen Safe Harbor This press release contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; regulatory discussions, submissions, filings, and approvals; the potential benefits, safety, and efficacy of our and our collaboration partners' products and investigational therapies; the anticipated benefits and potential of investments, actions to improve risk profile and productivity of R&D pipeline, collaborations, and business development activities; and our future financial and operating results. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'guidance,' 'hope,' 'intend,' 'may,' 'objective,' 'outlook,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'prospect,' 'should,' 'target,' 'will,' 'would,' and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. This press release includes, among others, forward-looking statements including: that Biogen is building on a new foundation with the goal of long-term sustainable growth in its commercial portfolio; the multi-billion dollar potential of its late-stage pipeline; that we believe there remains a significant long-term opportunity for our ongoing product launches including LEQEMBI; that we believe that continued execution against these key strategic elements, as well as a disciplined approach to business development, will allow us to generate long-term value for our shareholders by bringing innovative medicines to patients; and all statements and information under the heading "Full Year 2025 Financial Guidance". These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, factors relating to: our substantial dependence on revenue from our products and other payments under licensing, collaboration, acquisition or divestiture agreements; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the drivers for growing our business; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third parties, intellectual property, competitive and market challenges and regulatory compliance; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to technology, including our incorporation of new technologies such as artificial intelligence into some of our processes; risks related to use of information technology systems and potential impacts of any breakdowns, interruptions, invasions, corruptions, data breaches, destructions and/or other cybersecurity incidents of our systems or those of connected and/or third-party systems; problems with our manufacturing capacity, including our ability to manufacture products efficiently or adequately address global bulk supply risks; risks relating to management, personnel and other organizational changes, including our ability to attracting, retaining and motivating qualified individuals; risks related to the failure to comply with current and new legal and regulatory requirements, including judicial decisions, accounting standards, and tariff or trade restrictions; the risks of doing business internationally, including geopolitical tensions, acts of war and largescale crises; risks relating to investment in our manufacturing capacity; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media for our business, results of operations and financial condition; fluctuations in our operating results; risks related to investment in properties; risks relating to access to capital and credit markets to finance our present and future operations and business initiatives and obtain funding for such activities on favorable terms; risks related to indebtedness; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; change in control provisions in certain of our collaboration agreements; fluctuations in our effective tax rate and obligations in various jurisdictions in which we are subject to taxation; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned 'Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise. References: Tselios K, Gladman DD, Touma Z, et al. Disease course patterns in systemic lupus erythematosus. Lupus. 2019;28(1):114-122. Fanouriakis A, Tziolos N, Bertsias G, et al. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. doi:10.1136/annrheumdis-2020-218272 Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2002;16(5):847-58. Epub 2002/12/11. doi: 10.1053/berh.2002.0259. PubMed PMID: 12473278. Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis. 2016;75(1):136-41. Epub 2014/10/01. doi: 10.1136/annrheumdis-2014-206334. PubMed PMID: 25265938; PubMed Central PMCID: PMCPMC4717400. Pons-Estel GJ, Ugarte-Gil MF, Alarcón GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol. 2017;13(8):799-814. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605-20. Epub 2016/08/26. doi: 10.1038/nrrheum.2016.137. PubMed PMID: 27558659. Kheir JM, Guthridge CJ, Johnston JR, Adams LJ, Rasmussen A, Gross TF, et al. Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000247. Epub 2018/03/14. doi: 10.1136/lupus-2017-000247. PubMed PMID: 29531773; PubMed Central PMCID: PMCPMC5844376. Mehta B, Luo Y, Xu J, Sammaritano L, Salmon J, Lockshin M, et al. Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis. Ann Intern Med. 2019;171(3):164-71. Epub 2019/07/10. doi: 10.7326/M19-0120. PubMed PMID: 31284305. Bitencourt N, Bermas BL. Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding. Paediatr Drugs. Furie RA, Bruce IN, Dörner T, et al. Phase 2 randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate to severe active systemic lupus erythematosus (SLE). Rheumatology (Oxford).2021;60(11): 5397-407. (NCT04294667). A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO) 2023 [cited August 2024] Available at: Retrieved July 25, 2024. MEDIA CONTACTS:UCBAdriaan Snauwaert+32 497 70 23 BiogenJack Cox+1 781 464 INVESTOR CONTACTS:UCBAntje Witte+32 2 559 Power+ 1 781 464 2442IR@